ConductScience.org, home

Paper26190889

SGI-110: DNA Methyltransferase Inhibitor Oncolytic.

Griffiths EA and 5 others. Drugs Future, 2013. Cited by 57 papers, by iCite.

Cite this record

ConductScience Library. SGI-110: DNA Methyltransferase Inhibitor Oncolytic. Papers, record 26190889. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26190889

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
SGI-110: DNA Methyltransferase Inhibitor Oncolytic.
PubMed
Journal
Drugs Future
PubMed
Year
2013
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
57
iCite
Relative citation ratio, by iCite
1.41
iCite
Revised in PubMed
2024-03-23
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Griffiths EAE A
2Choy GG
3Redkar SS
4Taverna PP
5Azab MM
6Karpf ARA R

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
R01 CA116674NCI NIH HHSUnited StatesR01CA116674PubMed and NIH

Source NIH RePORTER

Download CSV of grants

References34

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
112011120Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.J Clin Oncol2002https://conductscience.org/library/papers/12011120PubMed
21606615Targeted mutation of the DNA methyltransferase gene results in embryonic lethality.Cell1992https://conductscience.org/library/papers/1606615PubMed
311498573The role of DNA methylation in mammalian epigenetics.Science2001https://conductscience.org/library/papers/11498573PubMed
415215868Essential role for de novo DNA methyltransferase Dnmt3a in paternal and maternal imprinting.Nature2004https://conductscience.org/library/papers/15215868PubMed
516532500Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.Cancer2006https://conductscience.org/library/papers/16532500PubMed
617616700Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides.Cancer Res2007https://conductscience.org/library/papers/17616700PubMed
710555141DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development.Cell1999https://conductscience.org/library/papers/10555141PubMed
823519618A rapid and sensitive assay for DNA-protein covalent complexes in living cells.Nucleic Acids Res2013https://conductscience.org/library/papers/23519618PubMed
916413389A pharmacodynamic study of 5-azacytidine in the P39 cell line.Exp Hematol2006https://conductscience.org/library/papers/16413389PubMed
106208998Effect of uridine on response of 5-azacytidine-resistant human leukemic cells to inhibitors of de novo pyrimidine synthesis.Cancer Res1984https://conductscience.org/library/papers/6208998PubMed
1117564707Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).Cancer Chemother Pharmacol2008https://conductscience.org/library/papers/17564707PubMed
1223138873Immunomodulatory activity of SGI-110, a 5-aza-2'-deoxycytidine-containing demethylating dinucleotide.Cancer Immunol Immunother2013https://conductscience.org/library/papers/23138873PubMed
1319230772Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.Lancet Oncol2009https://conductscience.org/library/papers/19230772PubMed
142425959Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients.Cancer Res1986https://conductscience.org/library/papers/2425959PubMed
159260521Cytosine methylation and the ecology of intragenomic parasites.Trends Genet1997https://conductscience.org/library/papers/9260521PubMed
1620564122A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer.Cancer2010https://conductscience.org/library/papers/20564122PubMed
1725316809The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer.Clin Cancer Res2014https://conductscience.org/library/papers/25316809PubMed
1811257100Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer.Hum Mol Genet2001https://conductscience.org/library/papers/11257100PubMed
196170748High-performance liquid chromatographic analysis of chemical stability of 5-aza-2'-deoxycytidine.J Pharm Sci1981https://conductscience.org/library/papers/6170748PubMed
206948829Cytosine arabinoside influx and nucleoside transport sites in acute leukemia.J Clin Invest1982https://conductscience.org/library/papers/6948829PubMed

See all 34 referencesDownload CSV of references

Cited by45

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 57 citations.

PMIDTitleJournalYearIn PapersSource
42435177Epigenetic Targeting in Myeloid Malignancies.Adv Exp Med Biol2026https://conductscience.org/library/papers/42435177PubMed
42196535Recent Advances in Searching for DNMT Inhibitors and Their Potential Application in Treating Human Diseases.Int J Mol Sci2026https://conductscience.org/library/papers/42196535PubMed
42194057Mechanism and Therapeutic Potential of Viral Mimicry in Cancer Immunotherapy.Biomolecules2026https://conductscience.org/library/papers/42194057PubMed
41987339DNMT3A in cancer: from epigenetic writer to oncogenic driver.Clin Epigenetics2026https://conductscience.org/library/papers/41987339PubMed
41673722Targeting epigenetic methylation: emerging diagnosis and therapeutic strategies in cancer.Exp Hematol Oncol2026https://conductscience.org/library/papers/41673722PubMed
40702903Guadecitabine improved relapse-free survival in high-risk acute myeloid leukemia and myelodysplastic syndrome patients after transplant: phase II results from a single center.Haematologica2026https://conductscience.org/library/papers/40702903PubMed
40641934The role of DNA methylation and demethylation in bladder cancer: a focus on therapeutic strategies.Front Oncol2025https://conductscience.org/library/papers/40641934PubMed
40025589Advances in epigenetic treatment of adult T-cell leukemia/lymphoma: a comprehensive review.Clin Epigenetics2025https://conductscience.org/library/papers/40025589PubMed
38231126Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial.Blood Adv2024https://conductscience.org/library/papers/38231126PubMed
37489400Therapeutic Applications of Azanucleoside Analogs as DNA Demethylating Agents.Epigenomes2023https://conductscience.org/library/papers/37489400PubMed
37297025Resistance of Leukemia Cells to 5-Azacytidine: Different Responses to the Same Induction Protocol.Cancers (Basel)2023https://conductscience.org/library/papers/37297025PubMed
37276510Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study.Blood Adv2023https://conductscience.org/library/papers/37276510PubMed
37190176What's Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach.Cancers (Basel)2023https://conductscience.org/library/papers/37190176PubMed
37056286Role and mechanism of DNA methylation and its inhibitors in hepatic fibrosis.Front Genet2023https://conductscience.org/library/papers/37056286PubMed
36979633Epigenetic Regulators of DNA Cytosine Modification: Promising Targets for Cancer Therapy.Biomedicines2023https://conductscience.org/library/papers/36979633PubMed
36934257Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells.J Exp Clin Cancer Res2023https://conductscience.org/library/papers/36934257PubMed
36834962Solute Carrier Family 29A1 Mediates In Vitro Resistance to Azacitidine in Acute Myeloid Leukemia Cell Lines.Int J Mol Sci2023https://conductscience.org/library/papers/36834962PubMed
36797244Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies.Signal Transduct Target Ther2023https://conductscience.org/library/papers/36797244PubMed
36707610LINE-1 ORF1p as a candidate biomarker in high grade serous ovarian carcinoma.Sci Rep2023https://conductscience.org/library/papers/36707610PubMed
360602655-methylcytosine turnover: Mechanisms and therapeutic implications in cancer.Front Mol Biosci2022https://conductscience.org/library/papers/36060265PubMed

See all 45 cited byDownload CSV of cited by

Genes18

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AFP174PubTator's text mininghttps://conductscience.org/library/genes/174NCBI Gene
CDA978PubTator's text mininghttps://conductscience.org/library/genes/978NCBI Gene
CDKN2A1029PubTator's text mininghttps://conductscience.org/library/genes/1029NCBI Gene
CTAG1A246100PubTator's text mininghttps://conductscience.org/library/genes/246100NCBI Gene
CYP4F34051PubTator's text mininghttps://conductscience.org/library/genes/4051NCBI Gene
DCK1633PubTator's text mininghttps://conductscience.org/library/genes/1633NCBI Gene
DNMT11786PubTator's text mininghttps://conductscience.org/library/genes/1786NCBI Gene
HGF3082PubTator's text mininghttps://conductscience.org/library/genes/3082NCBI Gene
ICAM13383PubTator's text mininghttps://conductscience.org/library/genes/3383NCBI Gene
MAGEA14100PubTator's text mininghttps://conductscience.org/library/genes/4100NCBI Gene
MAGEA104109PubTator's text mininghttps://conductscience.org/library/genes/4109NCBI Gene
MAGEA34102PubTator's text mininghttps://conductscience.org/library/genes/4102NCBI Gene
MIR29B1407024PubTator's text mininghttps://conductscience.org/library/genes/407024NCBI Gene
MUC1694025PubTator's text mininghttps://conductscience.org/library/genes/94025NCBI Gene
PMEL6490PubTator's text mininghttps://conductscience.org/library/genes/6490NCBI Gene
SLC29A12030PubTator's text mininghttps://conductscience.org/library/genes/2030NCBI Gene
SLC29A23177PubTator's text mininghttps://conductscience.org/library/genes/3177NCBI Gene
TWSG157045PubTator's text mininghttps://conductscience.org/library/genes/57045NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/26190889

GET https://conductscience.org/api/papers/v1/26190889/references?page=2